Fulcrum Therapeutics
Founded Year
2016Stage
IPO | IPOTotal Raised
$140MDate of IPO
7/18/2019Market Cap
0.18BStock Price
2.74About Fulcrum Therapeutics
Fulcrum Therapeutics (Nasdaq: FULC) is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum's therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes.
Missing: Fulcrum Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Fulcrum Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Fulcrum Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Fulcrum Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Fulcrum Therapeutics Patents
Fulcrum Therapeutics has filed 9 patents.
The 3 most popular patent topics include:
- Transcription factors
- Autosomal recessive disorders
- Muscular dystrophy
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
2/18/2021 | 2/28/2023 | Prodrugs, Stereochemistry, Epigenetics, Proteins, Enantiopure drugs | Grant |
Application Date | 2/18/2021 |
---|---|
Grant Date | 2/28/2023 |
Title | |
Related Topics | Prodrugs, Stereochemistry, Epigenetics, Proteins, Enantiopure drugs |
Status | Grant |
Latest Fulcrum Therapeutics News
May 5, 2023
News provided by Share this article Share this article NEW YORK, May 5, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC ). To receive updates on the lawsuit, fill out the form: The lawsuit seeks to recover losses for shareholders who purchased Fulcrum between March 3, 2022 and March 8, 2023. Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until June 27, 2023 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. According to a filed complaint, Fulcrum Therapeutics, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (i) the preclinical data submitted in support of FTX-6058 (an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies) showed safety concerns regarding potential hematological malignancies; (ii) the foregoing safety concerns increased the likelihood that the FDA would place a clinical hold on preclinical studies of FTX-6058; (iii) accordingly, the Company had overstated FTX-6058's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times. Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:
Fulcrum Therapeutics Frequently Asked Questions (FAQ)
When was Fulcrum Therapeutics founded?
Fulcrum Therapeutics was founded in 2016.
Where is Fulcrum Therapeutics's headquarters?
Fulcrum Therapeutics's headquarters is located at 26 Landsdowne Street, Cambridge.
What is Fulcrum Therapeutics's latest funding round?
Fulcrum Therapeutics's latest funding round is IPO.
How much did Fulcrum Therapeutics raise?
Fulcrum Therapeutics raised a total of $140M.
Who are the investors of Fulcrum Therapeutics?
Investors of Fulcrum Therapeutics include Foresite Capital, Section 32, Sanofi Ventures, SVB Leerink, Fidelity Investments and 7 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.